|

Cancer Clinical Trials in Utah

485 recruiting studies across 17 cities

All Trials in Utah

Phase
Trial Phase Location
Colon Adjuvant Chemotherapy Based on Evaluation of Residual DiseasePhase 2/3American Fork
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)Phase 3American Fork
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 3American Fork
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaPhase 3American Fork
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3American Fork
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerN/AAmerican Fork
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 3American Fork
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerPhase 3American Fork
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPhase 2Cedar City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPhase 2Cedar City
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2Draper
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationPhase 2Farmington
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialPhase 2/3Farmington
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPERPhase 2Farmington
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Phase 3Farmington
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck CancerPhase 3Farmington
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerPhase 3Farmington
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabPhase 3Farmington
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryPhase 2Farmington
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabPhase 3Farmington
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2Farmington
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasPhase 2Farmington
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaPhase 3Farmington
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Phase 3Murray
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)Phase 2Murray
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerPhase 3Murray
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCPhase 1/2Murray
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerPhase 3Murray
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerPhase 2Murray
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)Phase 3Murray
Improving Health Insurance Literacy Among Young Adult Cancer SurvivorsN/AMurray
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisPhase 2/3Murray
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous MelanomaN/AMurray
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted TherapyPhase 2/3Murray
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After ImmunotherapyPhase 2/3Murray
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyPhase 3Murray
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Phase 3Murray
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerPhase 1Murray
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialPhase 3Murray
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)Phase 3Murray
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Phase 3Ogden
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid TumorsPhase 1Ogden
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPhase 3Ogden
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 2Ogden
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3Ogden
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaPhase 3Ogden
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerPhase 2Ogden
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPhase 3Ogden
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles—Ogden
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPhase 3Pleasant Grove
(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisPhase 2Salt Lake City
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisPhase 2/3Salt Lake City
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast CancerPhase 2Salt Lake City
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)Phase 1/2Salt Lake City
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)Phase 1/2Salt Lake City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)—Salt Lake City
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...N/ASalt Lake City
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB TrialPhase 2Salt Lake City
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationPhase 1Salt Lake City
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal CancersPhase 1Salt Lake City
A Phase 1 Study of LNCB74 in Advanced Solid TumorsPhase 1Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)Phase 1/2Salt Lake City
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsPhase 1/2Salt Lake City
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseasePhase 1Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaPhase 1/2Salt Lake City
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaPhase 2Salt Lake City
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerPhase 2Salt Lake City
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPhase 2Salt Lake City
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaPhase 1/2Salt Lake City
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)Phase 2Salt Lake City
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)Phase 2Salt Lake City
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma SurvivorshipN/ASalt Lake City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesPhase 1/2Salt Lake City
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Phase 3Salt Lake City
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)Phase 3Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 3Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaPhase 3Salt Lake City
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3Salt Lake City
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaPhase 1Salt Lake City
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Salt Lake City
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)Phase 3Salt Lake City
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)Phase 3Salt Lake City
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1Salt Lake City
A Study of 177Lu-FAP-2286 in Advanced Solid TumorsPhase 1/2Salt Lake City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPhase 1/2Salt Lake City
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerPhase 1/2Salt Lake City
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerPhase 3Salt Lake City
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2Salt Lake City
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerPhase 2Salt Lake City
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPhase 1/2Salt Lake City
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)Phase 3Salt Lake City
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)Phase 1Salt Lake City
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsPhase 1Salt Lake City
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid TumorsPhase 2Salt Lake City
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWTPhase 2Salt Lake City
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid TumorsPhase 1Salt Lake City
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaEarly 1Salt Lake City
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePhase 3Salt Lake City
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsPhase 1/2Salt Lake City
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Phase 1Salt Lake City
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyPhase 3Salt Lake City
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 2Salt Lake City
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)Phase 1/2Salt Lake City
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerPhase 2Salt Lake City
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 MeningiomaPhase 2Salt Lake City
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsPhase 1Salt Lake City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )Phase 1Salt Lake City
A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaPhase 2Salt Lake City
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.Phase 1Salt Lake City
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationPhase 3Salt Lake City
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesPhase 1Salt Lake City
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)Phase 2Salt Lake City
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesPhase 1Salt Lake City
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesPhase 1/2Salt Lake City
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)Phase 3Salt Lake City
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Phase 1/2Salt Lake City
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationPhase 1/2Salt Lake City
A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsPhase 1Salt Lake City
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Phase 3Salt Lake City
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsPhase 3Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPhase 3Salt Lake City
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Phase 3Salt Lake City
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaPhase 1/2Salt Lake City
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Phase 1Salt Lake City
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 3Salt Lake City
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsPhase 1Salt Lake City
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTPhase 2Salt Lake City
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsPhase 3Salt Lake City
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic InformationPhase 2Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)Phase 1/2Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsPhase 1/2Salt Lake City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Phase 3Salt Lake City
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)Phase 2Salt Lake City
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Phase 2Salt Lake City
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPhase 3Salt Lake City
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPhase 3Salt Lake City
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerN/ASalt Lake City
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPhase 2Salt Lake City
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionPhase 2/3Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)Phase 3Salt Lake City
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3Salt Lake City
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal AdenocarcinomaPhase 3Salt Lake City
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsPhase 1Salt Lake City
A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsPhase 1Salt Lake City
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Phase 3Salt Lake City
A Study to Evaluate PEEL-224 in Patients With Advanced Solid TumorsPhase 1Salt Lake City
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid TumorsPhase 2Salt Lake City
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerPhase 1/2Salt Lake City
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPhase 3Salt Lake City
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)Phase 1/2Salt Lake City
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal CancerPhase 2/3Salt Lake City
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Phase 1/2Salt Lake City
A Study to Give Treatment Inside the Eye to Treat RetinoblastomaPhase 2Salt Lake City
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyPhase 3Salt Lake City
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesPhase 1/2Salt Lake City
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaPhase 3Salt Lake City
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid MalignanciesPhase 1Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsPhase 1Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantPhase 3Salt Lake City
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Phase 3Salt Lake City
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersPhase 1Salt Lake City
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)Phase 1/2Salt Lake City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerPhase 3Salt Lake City
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPhase 2/3Salt Lake City
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPhase 3Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)Phase 1/2Salt Lake City
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)Phase 3Salt Lake City
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerPhase 3Salt Lake City
Abatacept in Immune Checkpoint Inhibitor MyocarditisPhase 3Salt Lake City
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursPhase 3Salt Lake City
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsPhase 3Salt Lake City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Salt Lake City
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous PolyposisPhase 2Salt Lake City
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)—Salt Lake City
At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis)N/ASalt Lake City
Avapritinib With Decitabine in Patients With SM-AHNPhase 1Salt Lake City
BBO-11818 in Adult Subjects With KRAS Mutant CancerPhase 1Salt Lake City
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseasePhase 3Salt Lake City
Basal Cell Carcinoma Chemoprevention TrialPhase 3Salt Lake City
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients—Salt Lake City
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyPhase 2Salt Lake City
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Phase 1/2Salt Lake City
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaPhase 1/2Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaPhase 1Salt Lake City
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLPhase 2Salt Lake City
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaPhase 3Salt Lake City
Childhood Cancer Predisposition Study (CCPS)—Salt Lake City
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3Salt Lake City
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers—Salt Lake City
Collection of Tissue Samples for Cancer Research—Salt Lake City
ColoCare Study - Colorectal Cancer Cohort—Salt Lake City
Colonoscopy vs Stool Testing for Older Adults With Colon PolypsN/ASalt Lake City
Combination Therapy for the Treatment of Diffuse Midline GliomasPhase 2Salt Lake City
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT TrialPhase 2Salt Lake City
Community Services Navigation to Advance Health Equity in Breast Cancer ScreeningN/ASalt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerN/ASalt Lake City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Salt Lake City
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)Phase 2Salt Lake City
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Phase 2Salt Lake City
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)Phase 2Salt Lake City
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialPhase 2Salt Lake City
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPhase 3Salt Lake City
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers—Salt Lake City
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialPhase 3Salt Lake City
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLPhase 2Salt Lake City
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer ProgressionPhase 3Salt Lake City
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyPhase 3Salt Lake City
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPhase 2Salt Lake City
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaPhase 1/2Salt Lake City
Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net ClinicsN/ASalt Lake City
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaPhase 3Salt Lake City
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponsePhase 3Salt Lake City
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerPhase 1Salt Lake City
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaPhase 3Salt Lake City
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin CancersPhase 2Salt Lake City
Efficacy and Safety of the CG-100 Intraluminal Bypass DeviceN/ASalt Lake City
Embryonal Tumor With Multilayered RosettesPhase 2Salt Lake City
Enhancing Mammography Programs for Outreach, Wellness, Education, and Resources (EMPOWER) in Underserved Populations StudyN/ASalt Lake City
Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer TypeN/ASalt Lake City
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T TherapyPhase 2Salt Lake City
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)Phase 1/2Salt Lake City
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or AstrocytomaPhase 1Salt Lake City
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderPhase 2Salt Lake City
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete RemissionPhase 2Salt Lake City
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant DiseasePhase 2Salt Lake City
External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCLPhase 1Salt Lake City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3Phase 1Salt Lake City
Fabry Disease Registry & Pregnancy Sub-registry—Salt Lake City
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound SystemEarly 1Salt Lake City
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion MutationsPhase 1/2Salt Lake City
First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsPhase 1/2Salt Lake City
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerPhase 1Salt Lake City
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsN/ASalt Lake City
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBCPhase 2Salt Lake City
Galleri® in the Medicare Population.N/ASalt Lake City
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaPhase 1/2Salt Lake City
Guided Meditation During Radiation Therapy for Brain TumorsN/ASalt Lake City
Guided Meditation During Radiation Therapy for Breast and Gynecological MalignanciesPhase 3Salt Lake City
Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With CancerN/ASalt Lake City
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous WartsPhase 2/3Salt Lake City
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation TherapyPhase 1Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPhase 2Salt Lake City
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome—Salt Lake City
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)Phase 2Salt Lake City
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaPhase 1Salt Lake City
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerPhase 1/2Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell TransplantPhase 2Salt Lake City
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate CancerN/ASalt Lake City
Improving Care for Rural Patients With Solid TumorsN/ASalt Lake City
Increasing Germline Genetic Testing for Patients With CancerN/ASalt Lake City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPhase 3Salt Lake City
International Pachyonychia Congenita Research Registry—Salt Lake City
Ivosidenib as Post-HSCT Maintenance for AMLPhase 2Salt Lake City
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS AlterationPhase 1/2Salt Lake City
JAB-2485 Activity in Adult Patients With Advanced Solid TumorsPhase 1/2Salt Lake City
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Salt Lake City
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)Phase 1/2Salt Lake City
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)Phase 2Salt Lake City
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-NaïvePhase 1/2Salt Lake City
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies—Salt Lake City
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsPhase 2/3Salt Lake City
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)Phase 2Salt Lake City
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data—Salt Lake City
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesPhase 1Salt Lake City
Microvideos for Improving HPV Vaccination Among Childhood Cancer SurvivorsN/ASalt Lake City
Mobile Sun Health Intervention EnabLing Daily ProtectionN/ASalt Lake City
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed MedulloblastomaPhase 2Salt Lake City
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors—Salt Lake City
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell ImmunotherapyN/ASalt Lake City
Multimodal Telerehabilitation of Rural Patients With Advanced Prostate CancerN/ASalt Lake City
Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment—Salt Lake City
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on EnhertuPhase 2Salt Lake City
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)Phase 3Salt Lake City
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—Salt Lake City
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung CancerPhase 1Salt Lake City
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate CancerPhase 2Salt Lake City
PEEL-224, Vincristine and Temozolomide in Pediatric Solid TumorsPhase 1/2Salt Lake City
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) StudyN/ASalt Lake City
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPhase 3Salt Lake City
Pan Tumor Rollover StudyPhase 2Salt Lake City
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRASPhase 1Salt Lake City
Pancreatic Cancer Early Detection Consortium—Salt Lake City
Pembro With Radiation With or Without OlaparibPhase 2Salt Lake City
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabPhase 1/2Salt Lake City
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisPhase 1/2Salt Lake City
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Salt Lake City
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerPhase 3Salt Lake City
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsPhase 3Salt Lake City
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerPhase 3Salt Lake City
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ MalignanciesPhase 1Salt Lake City
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)Phase 2Salt Lake City
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL TrialPhase 2Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaPhase 2Salt Lake City
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIN/ASalt Lake City
Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window TrialPhase 2Salt Lake City
Project: Every Child for Younger Patients With Cancer—Salt Lake City
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy—Salt Lake City
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationPhase 2Salt Lake City
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy—Salt Lake City
QTX3034 in Patients With KRAS G12D MutationPhase 1Salt Lake City
Rural Adult and Youth Sun Protection StudyN/ASalt Lake City
SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer CareN/ASalt Lake City
SAVE Trial: SAfe Opioid Use Video EducationN/ASalt Lake City
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Phase 3Salt Lake City
SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier—Salt Lake City
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaPhase 3Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—Salt Lake City
Safety and Durability of Sirolimus for Treatment of LAM—Salt Lake City
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossPhase 1/2Salt Lake City
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsPhase 1/2Salt Lake City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Phase 2/3Salt Lake City
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid TumorsPhase 1Salt Lake City
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid TumorsPhase 1/2Salt Lake City
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 3Salt Lake City
Screening for AL Amyloidosis in Smoldering Multiple Myeloma—Salt Lake City
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)N/ASalt Lake City
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial CancerPhase 3Salt Lake City
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.Phase 2Salt Lake City
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid TumorsPhase 1/2Salt Lake City
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial—Salt Lake City
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBMPhase 3Salt Lake City
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain MetastasesPhase 3Salt Lake City
Stereotactic Radiosurgery Dose Escalation for Brain MetastasesPhase 1Salt Lake City
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentPhase 2Salt Lake City
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate CancPhase 2Salt Lake City
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerPhase 1/2Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaPhase 2Salt Lake City
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell CarcinomaPhase 3Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3Salt Lake City
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3Salt Lake City
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 3Salt Lake City
Study of INCA036978 in Participants With Myeloproliferative NeoplasmsPhase 1Salt Lake City
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell CarcinomaPhase 3Salt Lake City
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Phase 3Salt Lake City
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentPhase 1Salt Lake City
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid TumorsPhase 1Salt Lake City
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaPhase 2Salt Lake City
Study of ORIC-944 in Patients With Metastatic Prostate CancerPhase 1Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Phase 1Salt Lake City
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.Phase 1Salt Lake City
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)Phase 1/2Salt Lake City
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/2Salt Lake City
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/2Salt Lake City
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.Phase 1Salt Lake City
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaPhase 1/2Salt Lake City
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)Phase 3Salt Lake City
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPhase 2Salt Lake City
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and EfficacyPhase 1Salt Lake City
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerPhase 3Salt Lake City
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)Phase 3Salt Lake City
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraPhase 3Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaPhase 1Salt Lake City
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaPhase 1/2Salt Lake City
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2Salt Lake City
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsPhase 1/2Salt Lake City
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Phase 3Salt Lake City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair GenesPhase 1Salt Lake City
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Phase 1/2Salt Lake City
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal SarcomaPhase 3Salt Lake City
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerPhase 1/2Salt Lake City
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3Salt Lake City
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)Phase 1/2Salt Lake City
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIPhase 1/2Salt Lake City
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesPhase 1Salt Lake City
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) EpendymomaPhase 2Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Salt Lake City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Salt Lake City
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Phase 3Salt Lake City
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays—Salt Lake City
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerPhase 3Salt Lake City
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaPhase 3Salt Lake City
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyPhase 3Salt Lake City
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsPhase 2Salt Lake City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)Phase 2Salt Lake City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerPhase 3Salt Lake City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Salt Lake City
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaPhase 2Salt Lake City
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyPhase 3Salt Lake City
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary BlastomaPhase 3Salt Lake City
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialPhase 2Salt Lake City
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1Salt Lake City
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Phase 3Salt Lake City
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaPhase 2Salt Lake City
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal CavityPhase 2/3Salt Lake City
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur TrialPhase 2Salt Lake City
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or AstrocytomaPhase 1Salt Lake City
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentPhase 1/2Salt Lake City
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerPhase 3Salt Lake City
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaPhase 2Salt Lake City
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN StudyPhase 2/3Salt Lake City
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersPhase 2Salt Lake City
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPhase 3Salt Lake City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPhase 1/2Salt Lake City
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer—Salt Lake City
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)Phase 2Salt Lake City
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.Phase 3Salt Lake City
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Salt Lake City
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid TumorsPhase 2Salt Lake City
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerPhase 3Salt Lake City
Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsPhase 2Salt Lake City
Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer SurvivorsN/ASalt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy—Salt Lake City
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorPhase 2Salt Lake City
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemPhase 2Salt Lake City
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)Phase 3Salt Lake City
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Phase 1/2Salt Lake City
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Phase 1/2Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaPhase 2Salt Lake City
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological MalignanciesPhase 2Salt Lake City
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPhase 1/2Salt Lake City
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)Phase 2Salt Lake City
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)Phase 3Salt Lake City
XL092 in Patients With Metastatic Castration-Resistant Prostate CancerPhase 2Salt Lake City
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsPhase 2/3Salt Lake City
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma PatientsPhase 3Salt Lake City, UT
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Phase 2West Jordan
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)Phase 2West Valley City
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).Phase 1/2West Valley City
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsPhase 1/2West Valley City
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsPhase 1West Valley City
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPhase 1West Valley City
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsPhase 1/2West Valley City
A Phase 1 Study of BHV-1530 in Advanced Solid TumorsPhase 1West Valley City
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1West Valley City
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1West Valley City
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsPhase 1/2West Valley City
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLCPhase 1/2West Valley City
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsPhase 1/2West Valley City
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsPhase 1/2West Valley City
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerPhase 2West Valley City
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsPhase 1/2West Valley City
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)Phase 1/2West Valley City
A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsPhase 1West Valley City
A Study of ADRX-0405 in Subjects With Select Advanced Solid TumorsPhase 1West Valley City
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2West Valley City
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)Phase 1West Valley City
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesPhase 1West Valley City
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsPhase 1West Valley City
A Study of JNJ-98768111 in Participants With Advanced Prostate CancerPhase 1West Valley City
A Study of LY4175408 in Participants With Advanced CancerPhase 1West Valley City
A Study of MGC026 in Participants With Advanced Solid TumorsPhase 1West Valley City
A Study of MGC028 in Participants With Advanced Solid TumorsPhase 1West Valley City
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsPhase 1West Valley City
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid TumorsPhase 1/2West Valley City
A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsPhase 1West Valley City
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid TumorsPhase 1West Valley City
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsPhase 1West Valley City
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerPhase 1/2West Valley City
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsPhase 1West Valley City
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsPhase 1West Valley City
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsPhase 1West Valley City
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab AdizutecanPhase 2West Valley City
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian CancerPhase 1West Valley City
A Study to Evaluate ATX-898 in Participants With Advanced Solid TumorsPhase 1/2West Valley City
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid TumorsPhase 1West Valley City
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesPhase 1/2West Valley City
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)Phase 1West Valley City
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid TumorsPhase 1West Valley City
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPhase 1West Valley City
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsPhase 1West Valley City
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)Phase 1/2West Valley City
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsPhase 1/2West Valley City
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsPhase 1West Valley City
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCPhase 1/2West Valley City
First-Time-in-Human Study of GSK5471713 in Adults With mCRPCPhase 1/2West Valley City
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsPhase 1/2West Valley City
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor MalignanciesPhase 1/2West Valley City
First-in-human Study of 7MW4911 in GI CancerPhase 1/2West Valley City
First-in-human Study of DB-1419 for Advanced/Metastatic Solid TumorsPhase 1/2West Valley City
HMPL-A830 in Solid TumorsPhase 1/2West Valley City
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast CancerPhase 1West Valley City
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsPhase 1West Valley City
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPhase 1West Valley City
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2West Valley City
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2West Valley City
SNV1521 in Participants With Advanced Solid TumorsPhase 1West Valley City
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid TumorsPhase 1West Valley City
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast CancerPhase 1West Valley City
Study in Advanced Solid Tumor PatientsPhase 1/2West Valley City
Study of CP-383 in Patients With Advanced or Metastatic Solid TumorsPhase 1/2West Valley City
Study of Oral MRT-2359 With Apalutamide in Prostate CancerPhase 2West Valley City
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanPhase 1West Valley City
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPhase 1/2West Valley City
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological MalignanciesPhase 1West Valley City
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid MalignanciesPhase 1/2West Valley City

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.